September 30, 2016 / 8:01 PM / 10 months ago

BRIEF-U.S. court rules in favor of Depomed in its patent litigation for NUCYNTA

1 Min Read

Sept 30 (Reuters) - Depomed Inc :

* Depomed prevails in Nucynta franchise ANDA litigation providing market exclusivity until December 2025

* Company intends to appeal court's finding as it relates to infringement of '130 patent

* Depomed inc says '130 patent covers Nucynta ER until March 2029

* Court found U.S. patent nos. 7,994,364 and RE39,593 to be valid and infringed by defendants

* With court's ruling, Depomed expects market exclusivity until december 2025 for Nucynta ER, Nucynta and Nucynta oral solution

* Judge ruled in favor of depomed in company's patent litigation against all three filers of abbreviated new drug applications for Nucynta Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below